PURPOSE: Radical prostatectomy has significant side effects. Preoperative information predicting its long-term outcome would be valuable to patients and physicians. We determined whether pretreatment endorectal magnetic resonance imaging/magnetic resonance spectroscopic imaging predicts biochemical recurrence after radical prostatectomy. MATERIALS AND METHODS: Of 202 patients who underwent endorectal magnetic resonance imaging/magnetic resonance spectroscopic imaging from January 2000 to December 2002 before radical prostatectomy 130 satisfied study inclusion criteria and were included in analysis. We compared imaging factors with potential predictive capability to biochemical recurrence data, including magnetic resonance imaging risk score based on local disease extent and magnetic resonance spectroscopic imaging index lesion characteristics, such as the number of voxels and degree of metabolic abnormality (magnetic resonance spectroscopic imaging grade). We evaluated associations of these imaging variables with time to biochemical recurrence by Cox proportional hazards regression adjusted for known predictors of biochemical recurrence, such as stage, grade and prostate specific antigen. RESULTS: At a median 68-month followup there were 26 biochemical failures. Risk score, lesion volume and high grade voxels each correlated with time to biochemical recurrence. In a model combining clinical parameters risk score, lesion volume and at least 1 high grade voxel the magnetic resonance spectroscopic imaging variables remained significant but the magnetic resonance imaging score dropped out. CONCLUSIONS: Index lesion volume on magnetic resonance spectroscopic imaging and high grade magnetic resonance spectroscopic imaging voxels correlate with time to biochemical recurrence after radical prostatectomy even when adjusted for clinical data. Results suggest the preoperative predictive usefulness of endorectal magnetic resonance imaging/magnetic resonance spectroscopic imaging in patients considering radical prostatectomy.
PURPOSE: Radical prostatectomy has significant side effects. Preoperative information predicting its long-term outcome would be valuable to patients and physicians. We determined whether pretreatment endorectal magnetic resonance imaging/magnetic resonance spectroscopic imaging predicts biochemical recurrence after radical prostatectomy. MATERIALS AND METHODS: Of 202 patients who underwent endorectal magnetic resonance imaging/magnetic resonance spectroscopic imaging from January 2000 to December 2002 before radical prostatectomy 130 satisfied study inclusion criteria and were included in analysis. We compared imaging factors with potential predictive capability to biochemical recurrence data, including magnetic resonance imaging risk score based on local disease extent and magnetic resonance spectroscopic imaging index lesion characteristics, such as the number of voxels and degree of metabolic abnormality (magnetic resonance spectroscopic imaging grade). We evaluated associations of these imaging variables with time to biochemical recurrence by Cox proportional hazards regression adjusted for known predictors of biochemical recurrence, such as stage, grade and prostate specific antigen. RESULTS: At a median 68-month followup there were 26 biochemical failures. Risk score, lesion volume and high grade voxels each correlated with time to biochemical recurrence. In a model combining clinical parameters risk score, lesion volume and at least 1 high grade voxel the magnetic resonance spectroscopic imaging variables remained significant but the magnetic resonance imaging score dropped out. CONCLUSIONS: Index lesion volume on magnetic resonance spectroscopic imaging and high grade magnetic resonance spectroscopic imaging voxels correlate with time to biochemical recurrence after radical prostatectomy even when adjusted for clinical data. Results suggest the preoperative predictive usefulness of endorectal magnetic resonance imaging/magnetic resonance spectroscopic imaging in patients considering radical prostatectomy.
Authors: Bradford A Nelson; Scott B Shappell; Sam S Chang; Nancy Wells; Scott B Farnham; Joseph A Smith; Michael S Cookson Journal: BJU Int Date: 2006-06 Impact factor: 5.588
Authors: Peter Swindle; James A Eastham; Makoto Ohori; Michael W Kattan; Thomas Wheeler; Norio Maru; Kevin Slawin; Peter T Scardino Journal: J Urol Date: 2005-09 Impact factor: 7.450
Authors: M Graefen; J Noldus; U Pichlmeier; A Haese; P Hammerer; S Fernandez; S Conrad; R Henke; E Huland; H Huland Journal: Eur Urol Date: 1999 Impact factor: 20.096
Authors: Kristen L Zakian; Kanishka Sircar; Hedvig Hricak; Hui-Ni Chen; Amita Shukla-Dave; Steven Eberhardt; Manickam Muruganandham; Lanie Ebora; Michael W Kattan; Victor E Reuter; Peter T Scardino; Jason A Koutcher Journal: Radiology Date: 2005-03 Impact factor: 11.105
Authors: Andrew J Stephenson; Peter T Scardino; James A Eastham; Fernando J Bianco; Zohar A Dotan; Christopher J DiBlasio; Alwyn Reuther; Eric A Klein; Michael W Kattan Journal: J Clin Oncol Date: 2005-10-01 Impact factor: 44.544
Authors: Darko Pucar; Jason A Koutcher; Ankoor Shah; John P Dyke; Lawrence Schwartz; Howard Thaler; John Kurhanewicz; Peter T Scardino; W Kevin Kelly; Hedvig Hricak; Kristen L Zakian Journal: Clin Prostate Cancer Date: 2004-12
Authors: Barış Türkbey; Marcelino Bernardo; Maria J Merino; Bradford J Wood; Peter A Pinto; Peter L Choyke Journal: Diagn Interv Radiol Date: 2011-09-16 Impact factor: 2.630
Authors: Sung Yoon Park; Young Taik Oh; Dae Chul Jung; Nam Hoon Cho; Young Deuk Choi; Koon Ho Rha; Sung Joon Hong Journal: Eur Radiol Date: 2015-11-11 Impact factor: 5.315
Authors: Kinzya Grant; Maria L Lindenberg; Haytham Shebel; Yuxi Pang; Harsh K Agarwal; Marcelino Bernardo; Karen A Kurdziel; Baris Turkbey; Peter L Choyke Journal: Eur J Nucl Med Mol Imaging Date: 2013-05-07 Impact factor: 9.236